Results 1 to 10 of about 1,844 (152)

Safety and Efficacy of Remimazolam for General Anesthesia in Elderly Patients Undergoing Transurethral Surgery [PDF]

Health Science Reports
Background and Aims Remimazolam, a novel benzodiazepine, acts on the GABA receptor and is widely used for procedural sedation. To date, there are relatively few articles comparing remimazolam to propofol for general anesthesia in elderly urology patients.
Zhi Cheng, Jiachi Li, Ying Zhang, Guangrong Dai   +3 more
doaj   +3 more sources

Remimazolam attenuates traumatic brain injury-induced acute lung injury by suppressing pulmonary epithelial pyroptosis [PDF]

Journal of Neuroinflammation
Background and objectives TBI-induced acute lung injury (TBI-ALI), with an incidence rate of 22-25%, represents a critical determinant of secondary mortality. Remimazolam is a novel sedative that has shown potential for anti-inflammatory effects. However,
Chang Sun, Yi Zhang, Jiahan Wang, Bailun Wang, Angran Gu, Yuelan Wang, Changping Gu   +6 more
doaj   +2 more sources

Safety and efficacy of remimazolam besylate in patients undergoing colonoscopy: A multicentre, single-blind, randomized, controlled, phase Ⅲ trial

Frontiers in Pharmacology, 2022
Study objective: The objective of the study was to evaluate the safety and efficacy of remimazolam besylate versus propofol injection in patients undergoing colonoscopy.Design: A multicenter, randomized, non-inferiority, single-blind, parallel-controlled
Ximei Wang, Xiaolei Hu, Nianyue Bai, Lie Li, Lie Li, Min Zhang, Zhigang Cheng, Qulian Guo   +7 more
doaj   +1 more source

The effect of obstructive jaundice on the sensitivity of intravenous anesthetic of remimazolam: study protocol for a controlled multicenter trial

Trials, 2022
Background It is well known that obstructive jaundice could affect the pharmacodynamics of some anesthetics, and the sensitivity of some anesthetics would increase among icteric patients. Remimazolam is a new ultra-short-acting intravenous benzodiazepine
Wen Liu, Bin Yang, Jun-Wei Ji, Hua Yang, Hong-Hao Song, Hai-Bo Qiu, Jin-Chao Song   +6 more
doaj   +1 more source

Efficacy and safety of remimazolam besilate for sedation in outpatients undergoing impacted third molar extraction: a prospective exploratory study

BMC Oral Health, 2023
Background Dental treatments often cause anxiety, fear, and stress in patients. Intravenous sedation is widely used to alleviate these concerns, and various agents are employed for sedation.
Kana Oue, Aya Oda, Yoshitaka Shimizu, Tamayo Takahashi, Hisanobu Kamio, Utaka Sasaki, Serika Imamura, Eiji Imado, Akari Mukai, Mitsuru Doi, Miyuki Sakuma, Shigehiro Ono, Tomonao Aikawa, Mitsuhiro Yoshida   +13 more
doaj   +1 more source

Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials

Drugs in R&D, 2020
Background and Objectives Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation.
Marija Pesic, Thomas Stöhr, Joachim Ossig, Keith Borkett, Martin Donsbach, Van-Anh Dao, Lynn Webster, Frank Schippers   +7 more
doaj   +1 more source

Remimazolam Anesthesia for MitraClip Implantation in a Patient with Advanced Heart Failure

Case Reports in Anesthesiology, 2021
Remimazolam, a novel and ultrashort-acting benzodiazepine, has been available for general anesthesia in Japan. The administration of remimazolam does not induce injection pain, has been reported to have less cardiovascular depressant effects during ...
Tomoe Satoh, Noriaki Nishihara, Yasuaki Sawashita, Sho Ohno, Naoyuki Hirata, Michiaki Yamakage   +5 more
doaj   +1 more source

Comparison of postoperative nausea and vomiting between remimazolam and propofol: a propensity score-matched, retrospective, observational, single-center cohort study [PDF]

Korean Journal of Anesthesiology, 2023
Background Remimazolam is a novel ultrashort-acting benzodiazepine that has recently become available for general anesthesia. However, the incidence of postoperative nausea and vomiting (PONV) associated with remimazolam remains unknown.
Yuji Suzuki, Shingo Kawashima, Hiroshi Makino, Matsuyuki Doi, Yoshiki Nakajima   +4 more
doaj   +1 more source

Three cases of difficulty in achieving definitive loss of consciousness with remimazolam

JA Clinical Reports, 2022
Background Remimazolam is a novel, ultra-short-acting benzodiazepine used for general anesthesia. Because remimazolam is an emerging drug, the tolerance to remimazolam in benzodiazepine-taking patients has been unclear.
Mao Miyanishi, Toru Yaguramaki, Yasuhiro Maehara, Osamu Nagata   +3 more
doaj   +1 more source

Total intravenous anesthesia management with simultaneous use of remimazolam and propofol: A case series of three patients

SAGE Open Medical Case Reports, 2023
Remimazolam is an ultra-short-acting benzodiazepine anesthetic agent. Because of pharmacodynamic interactions in the sedation effect between benzodiazepines and propofol, the combination of remimazolam and propofol may allow for a dose reduction of each ...
Yuki Watanabe, Shinju Obara, Satoki Inoue   +2 more
doaj   +1 more source